Cardiovascular, renal and urogenital Circulatory System
Conditions
Interventions
Purpose
Primary aim
To co-create with patients, primary care practitioners and specialists a prototype care pathway for implementing personalised renal function monitoring and optimal interventions if
Sponsors
University of Liverpool
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patient sample: People with a diagnosis of heart failure as identified by their GP practice in England. An individual's self-reported acknowledgement of their formal diagnosis of heart failure is adequate to meet this study's objective, enabling patients to be recruited by other pathways in addition to GP practices, including third sector and PPIE channels. Professional sample: 1. Professionals working in the NHS or wider care settings in England 2. Stages 1 and 5 samples will include GPs, nurses and pharmacists 3. The stage 2 sample will include specialists and other key informants in addition to GPs, nurses and pharmacists
Exclusion criteria
Exclusion criteria: Patient sample: 1. People with heart failure who live outside of the UK. As the study initially focuses on developing a care pathway within England, we feel that our sample should reflect the experiences and views of patients currently living in England. 2. For patients recruited via a GP practice, we will ask practices to exclude patients with heart failure who: 2.1. Lack of mental capacity as identified by the practice 2.2. Are currently receiving inpatient treatment or admitted to the hospital for an exacerbation of their heart failure in the previous six weeks 3. For patients recruited via other routes, we will exclude patients if they are unable to give valid consent, but we will not include capacity assessments in the study design Professional sample: Professionals who work outside of England
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Training material linked to an algorithm-informed care pathway will be developed according to the TIDieR guidelines in preparation for Stage 6 (to be registered as a separate study) measured using data produced in Stages 1 to 5 throughout WP2 | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Current practices, barriers and facilitators to balancing renal and heart failure care measured using surveys and interviews conducted with stakeholders and identified using the Framework approach, with analysis that will produce material to be evaluated during the Stage 2 consensus workshop, during Stage 1 2. Components of the care pathway derived from evidence from WP1 and WP2 Stage 1 measured using consensus workshops with key stakeholder groups and agreed using the RAND/UCLA Appropriateness Method during Stage 2 3. Elements of the intervention measured using the data generated in the earlier Stages and evaluated using the APEASE criteria (acceptability, practicability, effectiveness/cost-effectiveness, affordability, and safety/side-effects) during Stage 3 4. Prototype training material measured using data produced during a series of multidisciplinary co-design workshops and input from a software development team during Stage 4 5. Prototype training material will be Beta tested measured using data produced during ‘think aloud’ interviews and built-in feedback from the prototype system during Stage 5 | — |
Countries
England, United Kingdom
Contacts
Public ContactAlison Gummery
Outcome results
None listed